PRP Joint Therapy Solutions in Inglewood, CA

CDC PLACES vs. JE: two files, not one brochure

CDC PLACES (2023, crude) estimates 14.5% of adults in Inglewood have diagnosed diabetes — 2.5 points above the U.S. 12% figure. Census city-proper population is 107,762. If you are adding prp joint therapy, start with that epidemiology and with Noridian Healthcare Solutions (JE) — not with a “near me” clinic listing. Hawk Medical ships nationwide; Joe Bradley’s own practice uses the same product classes.

Epidemiology is not a protocol

• Adult arthritis here is 21% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 14.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in California.
• California is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).
• PRP is autologous and not an HCT/P 361 allograft, but payers in JE still expect diagnosis-driven documentation. A 1-minute spin does not replace a medically necessary indication or a procedure note.

Uninsured mix and Medicare CTPs in the same building

JE reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Inglewood is 14.5% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic